Merck plans to invest US$29 million (€28 million) to open two new GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany.
The new manufacturing facilities will offer a comprehensive solution for every critical facet of mRNA development, production, and market deployment, encompassing not only the creation of mRNA products but also their rigorous testing.
This encompasses specialised analytical development and biosafety testing explicitly tailored for mRNA technologies, ensuring the highest quality and safety standards are met.
These state-of-the-art facilities play a crucial role in an ongoing investment programme designed at advancing mRNA technologies. In addition, this will also generate 75 new employment opportunities. This integrated approach simplifies processes and reduces complexities.
Type New Facility
Budget US$29 million (€28 million)